Photocure Norway New York Austria

for further information on our commercial partners.
The following safety information is solely included to comply with U.S. regulatory requirements: Important Risk & Safety Information for Cysview® (hexaminolevulinate HCl)

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com/news.

CONTACT:

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/photocure/r/new-bravo-study-publication-reinforces-clinical-benefits-of-blc-in-reducing-risk-of-bladder-cancer-r,c4118854

The following files are available for download:

https://mb.cision.com/Main/17498/4118854/3321033.pdf

Release

 

View original content:https://www.prnewswire.co.uk/news-releases/new-bravo-study-publication-reinforces-clinical-benefits-of-blc-in-reducing-risk-of-bladder-cancer-recurrence-302401805.html